Unparalleled experience in the development of unique oral dose delivery systems
We’re experts in taste masking & customized release for oral dosage forms
- Leading partner to >100 pharmaceutical companies across Branded, Specialty, Generic, Veterinarian and OTC segments
- Portfolio of 65+ commercial products globally across multiple therapeutic areas
- Expertise from product development to GMP approved commercial manufacturing
- Four R&D and manufacturing locations
- 800 employees
Sources:
- VitalStim Therapy (2005). Dysphagia: Fact sheet.
- Mennella, J. A., Spector, A. C., Reed, D. R., & Coldwell, S. E. (2013). The bad taste of medicines: overview of basic research on bitter taste. Clinical therapeutics, 35(8), 1225-1246.
- DeRoche, C., Macclaren, G., & Sonies, B. (2000). Pill Swallowing in America: A National Survey of Adults. Harris Interactive Survey.
- St. John’s University.
Our technologies address the needs of multiple, large patient populations
Dysphagia
- 1 in 17 people will develop dysphagia in their lifetime
- Indication specific dysphagia can result from a variety of diseases including stroke, MS, mental health disorders, GERD, and cancers of the throat
Pediatrics
- Unpleasant taste is the biggest barrier for completing treatment in pediatrics
- Proper taste masking increases compliance 53% to 90%
Geriatrics
- 26% of geriatric patients reported difficulty swallowing tablets and capsules
- Extended release formulations and titratable dosage forms are required to improve compliance
Adare has been recognized as a winner of the 2025 Outsourced Pharma CDMO Leadership Awards in the Small Molecule Dosage Form – Global category. The CDMO Leadership Awards recognizes the best contract development and manufacturing organizations across global and regional categories. This achievement reflects our ongoing commitment to advancing innovation, upholding the highest standards of quality, and consistently delivering excellence in pharmaceutical development.
For more information on the specialized delivery technologies provided by Adare, review the Related Resources and speak with one of our experts today.
Speak With An Expert
Nathan Dormer
Director, Drug Product Development
Nathan Dormer, Ph.D., is the Director of Drug Product Development at Adare Pharma Solutions and is responsible for pharmaceutical development activities at Adare’s Lenexa, KS and Philadelphia, PA facilities, where he supports a team of formulation scientists and analysts. He is a pharmaceutical scientist and bioengineer by training, with more than 16 years of experience developing microsphere-based solid oral and parenteral/implantable dosage forms in academic, innovator, and CDMO settings. Dr. Dormer earned his B.S. in Chemical Engineering and his Ph.D. (w/Honors) in Bioengineering from The University of Kansas while receiving NIH-sponsored Pharmaceutical Biotech Training.